| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 105.00 |
| Expiry date | 2024-01-19 |
| Day's range | 3.1000 - 3.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireNovartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2 Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a first
- GlobeNewswire
Novartis confirms Sandoz Spin-off for October 4, 2023
Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade credit rating for Sandoz confirmed: Moody’s, Baa2; S&P, BBBDebt financing of USD 3.75 billion (in various currencies) secured for Sandoz, supported by USD 1.25 billion revolving credit facilitySpin-off to be completed by way of a 1:5 distribution of Sandoz shares to Novartis shareholders and Sandoz ADRs
Simply Wall St.Novartis AG (VTX:NOVN) is a favorite amongst institutional investors who own 51%
Key Insights Institutions' substantial holdings in Novartis implies that they have significant influence over the...
